高级检索
    评价者：金浩生, 陈志鸿, 石宁, 文献合成者：吕玲. 卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌围手术期治疗的初步有效性与安全性[J]. 循证医学, 2021, 21(6): 337-340. DOI: 10.12019/j.issn.1671-5144.2021.06.005
    引用本文: 评价者：金浩生, 陈志鸿, 石宁, 文献合成者：吕玲. 卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌围手术期治疗的初步有效性与安全性[J]. 循证医学, 2021, 21(6): 337-340. DOI: 10.12019/j.issn.1671-5144.2021.06.005
    shu
    Reviewers: JIN Hao-sheng, CHEN Zhi-hong, SHI Ning, Literature Co-worker: LV Ling. Preliminary Efficacy and Safety of Perioperative Treatment of Camrelizumab Combined With Apatinib in Resectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 337-340. DOI: 10.12019/j.issn.1671-5144.2021.06.005
    Citation: Reviewers: JIN Hao-sheng, CHEN Zhi-hong, SHI Ning, Literature Co-worker: LV Ling. Preliminary Efficacy and Safety of Perioperative Treatment of Camrelizumab Combined With Apatinib in Resectable Hepatocellular Carcinoma[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 337-340. DOI: 10.12019/j.issn.1671-5144.2021.06.005
    shu

    卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌围手术期治疗的初步有效性与安全性

    Preliminary Efficacy and Safety of Perioperative Treatment of Camrelizumab Combined With Apatinib in Resectable Hepatocellular Carcinoma

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回